OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schultze-Koops H, Sleight A, Schiffrin E (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 76

Pages Range: 709-709

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Hôpital Claude Huriez

France (FR) Asklepios Kliniken

Germany (DE) Hôpitaux universitaires de Strasbourg (HUS) / University Hospital Strasbourg

France (FR) medius KLINIKEN gemeinnützige GmbH

Germany (DE) Ludwig-Maximilians-Universität (LMU)

Germany (DE) Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG)

Switzerland (CH) AB2 Bio Ltd.

Switzerland (CH) University of Montpellier / Université Montpellier

France (FR) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU)

France (FR) Pitié-Salpêtrière University Hospital / Hôpital universitaire Pitié-Salpêtrière

France (FR) Centre Hospitalier Universitaire de Bordeaux / CHU Bordeaux

France (FR) Universität zu Lübeck

Germany (DE) Charité - Universitätsmedizin Berlin

Germany (DE) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)

Switzerland (CH)

How to cite

APA:

Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Koetter, I.,... Schiffrin, E. (2017). OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE. (pp. 709-709).

MLA:

Gabay, C., et al. "OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE." 2017. 709-709.

BibTeX: Download